Intellipharmaceuticals International Inc.
IPCI
IPCI was delisted on the 20th of March, 2019.
13 hedge funds and large institutions have $6.58M invested in Intellipharmaceuticals International Inc. in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8% more funds holding
Funds holding: 12 → 13 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
5% less call options, than puts
Call options by funds: $20K | Put options by funds: $21K
13% less capital invested
Capital invested by funds: $7.6M → $6.58M (-$1.02M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$158K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$107K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$42.4K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$10.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$3.44M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$888K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$240K |
| 4 |
Neuberger Berman Group
New York
|
-$57K |
| 5 |
FNYS
First New York Securities
New York
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
1
Tekla Capital Management
Boston,
Massachusetts
| $5.2M | -$888K | -33,100 | -19% |
|
|
2
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $857K | -$240K | -8,932 | -28% |
|
|
3
Morgan Stanley
New York
| $219K | +$158K | +5,889 | New |
|
|
4
Ameriprise
Minneapolis,
Minnesota
| $148K | +$107K | +4,000 | New |
|
|
VKH
5
Virtu KCG Holdings
New York
| $120K | +$42.4K | +1,581 | +94% |
|
|
6
Bank of America
Charlotte,
North Carolina
| $15K | +$10.7K | +400 | +40,000% |
|
|
AIG
7
American International Group
New York
| $14.8K | – | – | – |
|
8
AllianceBernstein
Nashville,
Tennessee
| $3K | – | – | – |
|
9
Citigroup
New York
| $3K | +$1.96K | +73 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $3K | +$2.17K | +81 | New |
|
11
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
BC
12
Broadfin Capital
New York
| – | -$3.44M | -175,626 | Closed |
|
|
13
Neuberger Berman Group
New York
| – | -$57K | -2,900 | Closed |
|
|
FNYS
14
First New York Securities
New York
| – | -$26K | -1,302 | Closed |
|
IPCI Hedge Fund Activity: Q4 2013 in Review
13 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Intellipharmaceuticals International Inc. (IPCI) for Q4 2013, worth a combined $6.58M — down 13% from $7.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IPCI positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $158K. The largest seller was Broadfin Capital, exiting entirely with an estimated $3.44M sold.
- 13 institutional investors held Intellipharmaceuticals International Inc. (IPCI) as of Q4 2013, up from 12 in Q3 2013.
- Funds reported $6.58M of Intellipharmaceuticals International Inc. stock for Q4 2013, down 13% quarter-over-quarter.
- 4 funds opened new Intellipharmaceuticals International Inc. positions in Q4 2013 and 3 closed out, a net change of +1 holder.
- The largest Intellipharmaceuticals International Inc. buyer in Q4 2013 was Morgan Stanley, an estimated $158K added.
- The largest Intellipharmaceuticals International Inc. seller in Q4 2013 was Broadfin Capital, an estimated $3.44M sold.
Based on aggregated 13F filings for Q4 2013.